Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
Phase 3
Active, not recruiting
- Conditions
- Breast CancerLymphoma, Large B-Cell, DiffuseCardiotoxicityLeft Ventricular DysfunctionChemotherapy Effect
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Giulio Stefanini
- Target Recruit Count
- 80
- Registration Number
- NCT05728632
- Locations
- 🇮🇹
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
News
No news found